These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

183 related articles for article (PubMed ID: 36560407)

  • 1. Immunogenicity and Efficacy of Monovalent and Bivalent Formulations of a Virus-Like Particle Vaccine against SARS-CoV-2.
    Resch MD; Wen K; Mazboudi R; Mulhall Maasz H; Persaud M; Garvey K; Gallardo L; Gottlieb P; Alimova A; Khayat R; Morales J; Bielefeldt-Ohmann H; Bowen RA; Galarza JM
    Vaccines (Basel); 2022 Nov; 10(12):. PubMed ID: 36560407
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Protective efficacy of a plant-produced beta variant rSARS-CoV-2 VLP vaccine in golden Syrian hamsters.
    Lemmer Y; Chapman R; Abolnik C; Smith T; Schäfer G; Hermanus T; du Preez I; Goosen K; Sepotokele KM; Gers S; Suliman T; Preiser W; Shaw ML; Roth R; Truyts A; Chipangura J; Magwaza M; Mahanjana O; Moore PL; O'Kennedy MM
    Vaccine; 2024 Feb; 42(4):738-744. PubMed ID: 38238112
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Mucosal immunization with Ad5-based vaccines protects Syrian hamsters from challenge with omicron and delta variants of SARS-CoV-2.
    Braun MR; Martinez CI; Dora EG; Showalter LJ; Mercedes AR; Tucker SN
    Front Immunol; 2023; 14():1086035. PubMed ID: 36911687
    [TBL] [Abstract][Full Text] [Related]  

  • 4. SARS-CoV2 variant-specific replicating RNA vaccines protect from disease following challenge with heterologous variants of concern.
    Hawman DW; Meade-White K; Archer J; Leventhal SS; Wilson D; Shaia C; Randall S; Khandhar AP; Krieger K; Hsiang TY; Gale M; Berglund P; Fuller DH; Feldmann H; Erasmus JH
    Elife; 2022 Feb; 11():. PubMed ID: 35191378
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Pseudotyping Improves the Yield of Functional SARS-CoV-2 Virus-like Particles (VLPs) as Tools for Vaccine and Therapeutic Development.
    Zak AJ; Hoang T; Yee CM; Rizvi SM; Prabhu P; Wen F
    Int J Mol Sci; 2023 Sep; 24(19):. PubMed ID: 37834067
    [TBL] [Abstract][Full Text] [Related]  

  • 6. A Recombinant VSV-Based Bivalent Vaccine Effectively Protects against Both SARS-CoV-2 and Influenza A Virus Infection.
    Ao Z; Ouyang MJ; Olukitibi TA; Warner B; Vendramelli R; Truong T; Meilleur C; Zhang M; Kung S; Fowke KR; Kobasa D; Yao X
    J Virol; 2022 Sep; 96(18):e0133722. PubMed ID: 36069551
    [TBL] [Abstract][Full Text] [Related]  

  • 7. SARS-CoV-2 Virus-like Particles Produced by a Single Recombinant Baculovirus Generate Anti-S Antibody and Protect against Variant Challenge.
    Sullivan E; Sung PY; Wu W; Berry N; Kempster S; Ferguson D; Almond N; Jones IM; Roy P
    Viruses; 2022 Apr; 14(5):. PubMed ID: 35632656
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Construction and immunogenicity of SARS-CoV-2 virus-like particle expressed by recombinant baculovirus BacMam.
    Nguyen HT; Falzarano D; Gerdts V; Liu Q
    Microbiol Spectr; 2024 Jun; ():e0095924. PubMed ID: 38916311
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Cross-variant protection against SARS-CoV-2 infection in hamsters immunized with monovalent and bivalent inactivated vaccines.
    Ye ZW; Fan Y; Tang K; Ong CP; Luo C; Chung HL; Leong TL; Liang R; Lui WY; Zhou R; Cheng Y; Lu L; Cheung PH; Chan JF; Chen Z; Yuen KY; Yuan S; To KK; Jin DY
    Int J Biol Sci; 2022; 18(12):4781-4791. PubMed ID: 35874942
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Immunogenicity of adjuvanted plant-produced SARS-CoV-2 Beta spike VLP vaccine in New Zealand white rabbits.
    O'Kennedy MM; Abolnik C; Smith T; Motlou T; Goosen K; Sepotokele KM; Roth R; du Preez I; Truyts A; Stark HC; Magwaza M; Mahanjana O; Verschoor JA; Moore PL; Lemmer Y
    Vaccine; 2023 Mar; 41(13):2261-2269. PubMed ID: 36868876
    [TBL] [Abstract][Full Text] [Related]  

  • 11. RBD-VLP Vaccines Adjuvanted with Alum or SWE Protect K18-hACE2 Mice against SARS-CoV-2 VOC Challenge.
    Wong TY; Russ BP; Lee KS; Miller OA; Kang J; Cooper M; Winters MT; Rodriguez-Aponte SA; Dalvie NC; Johnston RS; Rader NA; Wong ZY; Cyphert HA; Martinez I; Shaligram U; Batwal S; Lothe R; Chandrasekaran R; Nagar G; Rajurkar M; Rao H; Bevere JR; Barbier M; Love JC; Damron FH
    mSphere; 2022 Aug; 7(4):e0024322. PubMed ID: 35968964
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Immunogenicity and efficacy of XBB.1.5 rS vaccine against EG.5.1 variant of SARS-CoV-2 in Syrian hamsters.
    Boon J; Soudani N; Bricker T; Darling T; Seehra K; Patel N; Guebre-Xabier M; Smith G; Suthar M; Ellebedy A; Davis-Gardner M
    Res Sq; 2024 Feb; ():. PubMed ID: 38405749
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Beta-containing bivalent SARS-CoV-2 protein vaccine elicits durable broad neutralization in macaques and protection in hamsters.
    Berry C; Pavot V; Anosova NG; Kishko M; Li L; Tibbitts T; Raillard A; Gautheron S; Cummings S; Bangari DS; Kar S; Atyeo C; Deng Y; Alter G; Gutzeit C; Koutsoukos M; Chicz RM; Lecouturier V
    Commun Med (Lond); 2023 May; 3(1):75. PubMed ID: 37237062
    [TBL] [Abstract][Full Text] [Related]  

  • 14. A virus-like particle candidate vaccine based on CRISPR/Cas9 gene editing technology elicits broad-spectrum protection against SARS-CoV-2.
    Wang W; Wang S; Meng X; Zhao Y; Li N; Wang T; Feng N; Yan F; Xia X
    Antiviral Res; 2024 May; 225():105854. PubMed ID: 38447647
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Development and preclinical evaluation of virus-like particle vaccine against COVID-19 infection.
    Yilmaz IC; Ipekoglu EM; Bulbul A; Turay N; Yildirim M; Evcili I; Yilmaz NS; Guvencli N; Aydin Y; Gungor B; Saraydar B; Bartan AG; Ibibik B; Bildik T; Baydemir İ; Sanli HA; Kayaoglu B; Ceylan Y; Yildirim T; Abras I; Ayanoglu IC; Cam SB; Ciftci Dede E; Gizer M; Erganis O; Sarac F; Uzar S; Enul H; Adiay C; Aykut G; Polat H; Yildirim IS; Tekin S; Korukluoglu G; Zeytin HE; Korkusuz P; Gursel I; Gursel M
    Allergy; 2022 Jan; 77(1):258-270. PubMed ID: 34519053
    [TBL] [Abstract][Full Text] [Related]  

  • 16. SARS-CoV-2 bivalent mRNA vaccine with broad protection against variants of concern.
    Ma Q; Li M; Ma L; Zhang C; Zhang H; Zhong H; Wen J; Wang Y; Yan Z; Xiong W; Wu L; Guo J; Yang W; Yang Z; Zhang B
    Front Immunol; 2023; 14():1195299. PubMed ID: 37292197
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Assessment of Immunogenicity and Efficacy of CV0501 mRNA-Based Omicron COVID-19 Vaccination in Small Animal Models.
    Roth N; Gergen J; Kovacikova K; Mueller SO; Ulrich L; Schön J; Halwe NJ; Fricke C; Corleis B; Dorhoi A; Hoffmann D; Beer M; Maione D; Petsch B; Rauch S
    Vaccines (Basel); 2023 Jan; 11(2):. PubMed ID: 36851196
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Pathogenicity of SARS-CoV-2 Omicron (R346K) variant in Syrian hamsters and its cross-neutralization with different variants of concern.
    Mohandas S; Yadav PD; Sapkal G; Shete AM; Deshpande G; Nyayanit DA; Patil D; Kadam M; Kumar A; Mote C; Jain R
    EBioMedicine; 2022 May; 79():103997. PubMed ID: 35405385
    [TBL] [Abstract][Full Text] [Related]  

  • 19. A Heterologous Challenge Rescues the Attenuated Immunogenicity of SARS-CoV-2 Omicron BA.1 Variant in Syrian Hamster Model.
    Ma J; Liu X; Zhou M; Chen P; Chen R; Wang J; Zhu H; Wu K; Ye J; Zhang Y; Yuan Q; Tang Q; Yuan L; Cheng T; Guan Y; Xia N
    J Virol; 2023 Feb; 97(2):e0168422. PubMed ID: 36651747
    [TBL] [Abstract][Full Text] [Related]  

  • 20. An Efficient and Scalable Method for the Production of Immunogenic SARS-CoV-2 Virus-like Particles (VLP) from a Mammalian Suspension Cell Line.
    Hirschberg S; Ghazaani F; Ben Amor G; Pydde M; Nagel A; Germani S; Monica L; Schlör A; Bauer H; Hornung J; Voetz M; Dwai Y; Scheer B; Ringel F; Kamal-Eddin O; Harms C; Füner J; Adrian L; Pruß A; Schulze-Forster K; Hanack K; Kamhieh-Milz J
    Vaccines (Basel); 2023 Sep; 11(9):. PubMed ID: 37766145
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.